Hope for RA patients: drug may heal bone erosion

NCT ID NCT05955066

Recruiting now Disease control Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether baricitinib, a JAK inhibitor, can heal bone erosion in people with active rheumatoid arthritis. Sixty adults with moderate-to-severe RA and at least one bone erosion will receive either baricitinib or a placebo for 24 weeks. The main goal is to see if the drug reduces erosion size, measured by a special CT scan.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Baricitinib (Olumiant) 4 mg daily
What this could lead to: If successful, this could show that JAK inhibitors help repair bone damage in rheumatoid arthritis, potentially leading to better long-term joint health.
What could go wrong: This is a small, early-phase study with only 60 participants, so results may not apply to everyone. The treatment may not heal bone erosion, and JAK inhibitors carry risks like infections and blood clots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS

Contacts and locations

Locations

The Chinese University of Hong Kong
RECRUITING

Hong Kong, Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.